Amit Verma, MD, Guillermo Garcia-Manero, MD, and Rami Komrokji, MD
In this segment, “Emerging Therapeutics for MDS,” Amit Verma, MD, Guillermo Garcia-Manero, MD and Rami Komrokji, MD highlight promising agents in development for lower- and higher-risk MDS.
No new agents have been approved for myelodysplastic syndromes (MDS) in the past decade. However, an array of novel agents with diverse mechanisms are now in development. These include TGF-β modulators, P53 inactivators, ALK receptor inhibitors, immunotherapies (e.g., immune checkpoint inhibitors), and new hypomethylating agents (HMAs). We could possibly have several new therapies approved for MDS in the next few years.